354 related articles for article (PubMed ID: 36896445)
21. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
23. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
24. Emerging delivery strategy for oncolytic virotherapy.
Zhu J; Ma J; Huang M; Deng H; Shi G
Mol Ther Oncol; 2024 Jun; 32(2):200809. PubMed ID: 38845744
[TBL] [Abstract][Full Text] [Related]
25. Progress of oncolytic virotherapy for neuroblastoma.
Chen XT; Dai SY; Zhan Y; Yang R; Chen DQ; Li Y; Zhou EQ; Dong R
Front Pediatr; 2022; 10():1055729. PubMed ID: 36467495
[TBL] [Abstract][Full Text] [Related]
26. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
27. Determinants of the efficacy of viro-immunotherapy: A review.
de Graaf JF; Huberts M; Fouchier RAM; van den Hoogen BG
Cytokine Growth Factor Rev; 2020 Dec; 56():124-132. PubMed ID: 32919831
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in oncolytic virus therapy for hepatocellular carcinoma.
Zhu L; Lei Y; Huang J; An Y; Ren Y; Chen L; Zhao H; Zheng C
Front Oncol; 2023; 13():1172292. PubMed ID: 37182136
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.
Gao P; Ding G; Wang L
Transl Cancer Res; 2021 Oct; 10(10):4290-4302. PubMed ID: 35116288
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S; Fukuhara H; Todo T
Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
Front Immunol; 2022; 13():950079. PubMed ID: 36703982
[TBL] [Abstract][Full Text] [Related]
34. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers.
Scanlan H; Coffman Z; Bettencourt J; Shipley T; Bramblett DE
Front Oncol; 2022; 12():940019. PubMed ID: 35965554
[TBL] [Abstract][Full Text] [Related]
35. Advances in the clinical development of oncolytic viruses.
Li K; Zhao Y; Hu X; Jiao J; Wang W; Yao H
Am J Transl Res; 2022; 14(6):4192-4206. PubMed ID: 35836877
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic Viruses and Cancer Immunotherapy.
Malhotra J; Kim ES
Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.
Lee NH; Kim M; Oh SY; Kim SG; Kwon HC; Hwang TH
Oncotarget; 2017 Jan; 8(1):1213-1225. PubMed ID: 27901484
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
